Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis.

Abstract

The development and utilization of monoclonal antibodies (mAbs) have been of great interest in all fields of medicine. A substantial increase in the production and development of mAbs has occurred because these biologic agents are proving to be effective and less toxic given their targeted mechanism of action. However, data are limited on coadministration of two or more mAbs. With the increasing availability of mAbs and the comorbidities of some patients, assessment is needed of the ability to safely use multiple mAbs for an individual patient. Although the efficacy of coadministered mAbs may be inferred from their specific targets, we could find no literature reporting such a finding. Herein, we report our experience using two different classes of mAbs to treat hypereosinophilic syndrome and ulcerative colitis in a single patient.

• Authors: Bhavisha Patel, Joseph H Butterfield, Catherine R Weiler, Sunanda V Kane
• Journal: Monoclonal antibodies in immunodiagnosis and immunotherapy (Monoclon Antib Immunodiagn Immunother) Vol. 35 Issue 6 Pg. 300-303 (Dec 2016) ISSN: 2167-9436 [Electronic] United States
• PMID: 27911676 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• Immunologic Factors
• mepolizumab
• Infliximab

Topics

• Adult
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Colitis, Ulcerative (drug therapy, immunology, pathology)
• Drug Tolerance
• Eosinophils (drug effects, immunology, pathology)
• Female
• Gastrointestinal Agents (therapeutic use)
• Humans
• Hypereosinophilic Syndrome (drug therapy, immunology, pathology)
• Immunologic Factors (therapeutic use)
• Infliximab (therapeutic use)
• Treatment Outcome